Patents by Inventor Chung-Ling Liang

Chung-Ling Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240058369
    Abstract: Provided a method of treating ocular surface damage caused by an eye disease or eye injury like dry eye disease, chemical or physical injury, infection, neurosensory abnormalities and unspecified etiologies in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of microRNA-328 antagonist.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 22, 2024
    Inventors: Suh-Hang JUO, Chung-Ling LIANG
  • Patent number: 11040055
    Abstract: Methods and compositions for treating diabetic retinopathy employ an ophthalmic, topical formulation of micro-RNA 195 packaged in or on a nanoparticle or vesicle.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 22, 2021
    Assignee: China Medical University
    Inventors: Suh-Hang Hank Juo, Chung-Ling Liang, Tzu-Ming Wang
  • Publication number: 20190321389
    Abstract: Methods and compositions for treating diabetic retinopathy employ an ophthalmic, topical formulation of micro-RNA 195 packaged in or on a nanoparticle or vesicle.
    Type: Application
    Filed: December 12, 2017
    Publication date: October 24, 2019
    Inventors: Suh-Hang Hank JUO, Chung-Ling LIANG, Tzu-Ming WANG
  • Patent number: 10179913
    Abstract: The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 15, 2019
    Assignee: Kaohsiung Medical University
    Inventors: Suh-Hang H. Juo, Edward Hsi, Chung-Ling Liang
  • Publication number: 20180216109
    Abstract: The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang H. Juo, Edward Hsi, Chung-Ling Liang
  • Patent number: 9670489
    Abstract: The present disclosure provides a method for treating and/or preventing myopia, including: administering an RNA interference (RNAi) to a subject, wherein the RNA interference is capable of counteracting another RNA interference, and the other RNA interference is an RNA interference capable of inhibiting an expression of PAX-6 gene, and the RNA interference capable of inhibiting an expression of PAX-6 gene comprises microRNA-328.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: June 6, 2017
    Assignee: Kaohsiung Medical University
    Inventors: Suh-Hang Juo, Ku-Chung Chen, Edward Hsi, Chung-Ling Liang
  • Publication number: 20160010087
    Abstract: The present disclosure provides a method for treating and/or preventing myopia, including: administering an RNA interference (RNAi) to a subject, wherein the RNA interference is capable of counteracting another RNA interference, and the other RNA interference is an RNA interference capable of inhibiting an expression of PAX-6 gene, and the RNA interference capable of inhibiting an expression of PAX-6 gene comprises microRNA-328.
    Type: Application
    Filed: March 31, 2015
    Publication date: January 14, 2016
    Inventors: Suh-Hang JUO, Ku-Chung CHEN, Edward HSI, Chung-Ling LIANG
  • Publication number: 20120245108
    Abstract: The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 27, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang Hank Juo, Wen-Wen Chou, Jing-Mei Wu, Chung-Ling Liang
  • Publication number: 20110129838
    Abstract: A method and kit for determining an increased risk of developing myopia in a subject is provided by detecting an SNP in the BICD1 gene. The SNP is selected from a group consisting of rs10844126 (A/C), rs1151029 (A/T), rs2650122 (C/T), rs10771923 (A/G), rs1151009 (T/C), rs2125173 (A/G) and rs161959 (C/G). When the presence of the risk allele associated with myopia is detected at the SNP, the subject is determined in an increased risk of developing myopia.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 2, 2011
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang Hank Juo, Chung-Ling Liang, Edward Hsi